Family · immune
Thymogen
Glutamyl-Tryptophan (L-Glu-L-Trp, Glu-Trp); brand: Thymogen
Thymogen is a synthetic dipeptide of glutamic acid and tryptophan (L-Glu-L-Trp), identified as an active fragment isolated from the calf-thymus peptide preparation Thymalin. In preclinical models it behaves as an immunomodulator rather than a straightforward stimulant: reported effects include promotion of T-cell differentiation and maturation, modulation of intracellular cyclic-nucleotide balance, and enhancement of neutrophil chemotaxis and phagocytosis, tending to normalise rather than maximally drive immune responses. It is part of the 'peptide bioregulator' framework developed by Khavinson and colleagues in the former USSR. The specific molecular receptors and pathways are not fully defined by modern independent standards, and much of the mechanistic account rests on older, mostly Russian-language literature.
The evidence base is honestly limited and heavily weighted toward older Russian research. Mechanistic and immunological claims trace largely to Morozov and Khavinson's work on natural and synthetic thymic peptides (1997), and animal data such as Anisimov et al. (2000) report that L-Glu-L-Trp slowed aging markers and reduced spontaneous tumour incidence in rats. Independent, well-controlled Western human trials are scarce, and the compound has not been evaluated by the FDA or EMA. Claims should be read against a small, largely single-region and industry-adjacent literature rather than a robust modern evidence base.
- Research into T-cell differentiation and immune-cell regulation
- Explored as an adjuvant in infection and immunosuppression models
- Preclinical aging and spontaneous-carcinogenesis studies in rodents
- Historical clinical use in its region of registration for secondary immunodeficiency (limited independent verification)
Educational overview only — no dosing instructions in the public hub.
Long-term human safety outside its region of registration is not established by modern independent standards, and the supporting trials are small and mostly older. As with any immunomodulator, altering immune balance carries theoretical risks that are not well quantified here. For material sold as 'research use only', unverified sourcing and purity are the dominant practical concerns.
A third-party CoA covering identity, purity (HPLC) and mass confirmation (MS) is the minimum verification. As a very short dipeptide it is comparatively simple to synthesise, but confirming that a sample is the correct L-Glu-L-Trp sequence at stated purity still requires proper analytics.
Registered as a medicine in Russia (and some neighbouring countries); research-use-only elsewhere and not approved by the FDA or EMA. It is not an authorised medicine in the EU, UK or US.
Frequently asked questions
- What is Thymogen used for?
- Research into T-cell differentiation and immune-cell regulation. Explored as an adjuvant in infection and immunosuppression models. Preclinical aging and spontaneous-carcinogenesis studies in rodents. Historical clinical use in its region of registration for secondary immunodeficiency (limited independent verification). The evidence base is honestly limited and heavily weighted toward older Russian research. Mechanistic and immunological claims trace largely to Morozov and Khavinson's work on natural and synthetic thymic peptides (1997), and animal data such as Anisimov et al. (2000) report that L-Glu-L-Trp slowed aging markers and reduced spontaneous tumour incidence in rats. Independent, well-controlled Western human trials are scarce, and the compound has not been evaluated by the FDA or EMA. Claims should be read against a small, largely single-region and industry-adjacent literature rather than a robust modern evidence base.
- Is Thymogen legal in Europe?
- Registered as a medicine in Russia (and some neighbouring countries); research-use-only elsewhere and not approved by the FDA or EMA. It is not an authorised medicine in the EU, UK or US.
- What are the risks and side effects of Thymogen?
- Long-term human safety outside its region of registration is not established by modern independent standards, and the supporting trials are small and mostly older. As with any immunomodulator, altering immune balance carries theoretical risks that are not well quantified here. For material sold as 'research use only', unverified sourcing and purity are the dominant practical concerns.
- How is the quality of Thymogen assessed?
- A third-party CoA covering identity, purity (HPLC) and mass confirmation (MS) is the minimum verification. As a very short dipeptide it is comparatively simple to synthesise, but confirming that a sample is the correct L-Glu-L-Trp sequence at stated purity still requires proper analytics.